Laurent Bertoletti Highlights Evolving Role of Anticoagulation in Pulmonary Hypertension Treatment
Laurent Bertoletti, University Professor and Hospital Practitioner at Jean Monnet University, Saint-Etienne, shared on LinkedIn:
”Thank you to the scientific council of the French Days of Pulmonary Hypertension RespiFil for the invitation to present an update on the treatment anticoagulant in pulmonary hypertension.
It is an honour to be able to share data from the French registry and to discuss a topic that is as debated as it is crucial for patient care.
The prescription of anticoagulants now seems to be restricted to patients with a validated indication such as a history of MTEV or atrial fibrillation.
The next collective objective is to determine the best therapeutic antithrombotic strategy, in patients with PH-TEC or PH and a validated indication.”
Stay updated with Hemostasis Today.
-
Jul 27, 2026, 15:40Afila Thasnim: Blood Crossmatching Challenges and Safe Transfusion Decisions
-
Jul 27, 2026, 14:30William McKeown Elected Vice-President of the EHC
-
Jul 27, 2026, 13:54Nahid A. Qushmaq: Advancing Anticoagulation Through Factor XI/XIa Inhibition
-
Jul 27, 2026, 13:45The Essentials of FFP Dosing and Monitoring – ICHCC
-
Jul 27, 2026, 13:27Antonio Lauletta: Distinguishing Sporadic and ICI-Related MG-Myositis Overlap
-
Jul 27, 2026, 13:15Satyam Arora: Welcoming the New ISBT Board and Looking Ahead
-
Jul 27, 2026, 13:03Jeff Parke: Why We Are Losing Viable Kidneys in Transit
-
Jul 27, 2026, 12:58George Hajishengallis: A New Era in Periodontal Disease Treatment
-
Jul 27, 2026, 12:54Elena Masselli: Can Statins Enhance Peginterferon Therapy in MPNs?